Please login to the form below

Not currently logged in
Email:
Password:

Valeant acquires AB Sanitas

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m

Canada-based Valeant Pharmaceuticals International is to acquire Lithuanian speciality pharmaceutical company AB Sanitas in a two-stage deal worth €314m.

AB Sanitas sells about 390 generic products in nine Central and Eastern European countries. Its largest markets are Poland, Russia and Lithuania.

Valeant said the major shareholders of AB Sanitas have agreed to sell an 87 per cent stake in the company. That portion of the deal is expected to close during the third quarter, and Valeant said it will then start an offer for the remaining shares.

The Ontario-based company expects to assume €50m ($70.3m) in debt as part of the deal. The acquisition is expected to close during the fourth quarter of 2011.

AB Sanitas is based in Kaunas and develops its own dermatology, ophthalmology and hospital injectable drugs.

26th May 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...